價格 | ¥398 | ¥892 | ¥1360 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Sobetirome | 英文名稱:Sobetirome |
CAS:211110-63-3 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.25% | 產(chǎn)品類別: 抑制劑 |
貨號: T5313 |
名稱 | Sobetirome |
描述 | Sobetirome (IACS-010759) is a selective agonist of thyroid hormone receptor β (TRβ) and binds selectively to TRβ-1 (EC50: 0.16 μM). |
動物實驗 | Briefly, 20 μg of a pT3-EF5α-hMet-V5 and pT3-EF5α-S45Y-β-catenin-Myc combination along with the transposase in a ratio of 25:1 were diluted in 2 mL of normal saline (0.9% NaCl), filtered through a 0.22-μm filter, and injected into the lateral tail vein of 23 FVB mice that were around 6 weeks old, in 5 to 7 seconds. These mice are referred henceforth as hMet-mutant-β-catenin mice. Four weeks after injection, hMet-mutant-β-catenin mice were randomized into two groups. One group was kept on a basal diet (n = 12), and another group was switched to a GC-1–supplemented diet (5 mg/kg of diet) (n = 11). Animals on control diet were sacrificed at either 21 days (n = 8) or 10 days (n = 4) after initiation of the diet. Similarly, animals on the GC-1 diet were sacrificed at either 21 days (n = 7) or 10 days (n = 4) after initiation of the diet. The animals were given access to food and water ad libitum with a 12-hour light/dark daily cycle. One intraperitoneal injection of bromodeoxyuridine (BrdU) was performed on day 9 during 10 days of GC-1 or basal diet treatment, and livers were harvested 24 hours later [2]. |
體外活性 | GC-1特意設計用于選擇性地結合于TRβ(EC50:TRα-1為0.58 μM,TRβ-1為0.16 μM)[1]。作為甲狀腺激動劑,GC-1通過Wnt/β-catenin信號通路誘導肝細胞增殖,可能在急性及慢性肝功能不全中促進再生[2]。 |
體內活性 | 注射四周后,小鼠被喂養(yǎng)含5 mg/kgSobetirome或基礎飲食,持續(xù)10天或21天。Sobetirome的治療在10天或21天內顯著降低了腫瘤負擔[2]。Sobetirome治療使得標準飲食下的小鼠血清膽固醇水平降低了25%,血清甘油三酯降低了75%,同時減輕了飲食引起的高膽固醇血癥[3]。Sobetirome(50或100 mug/100 g體重)顯著促進了大鼠肝細胞在無組織損傷的情況下的增殖,并導致了大量的胰腺細胞增殖[4]。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 30 mg/mL (91.4 mM) Ethanol : 30 mg/mL |
關鍵字 | QRX431 | Inhibitor | IACS010759 | inhibit | IACS 010759 | Thyroid Hormone Receptor | QRX 431 | Sobetirome | THR |
相關產(chǎn)品 | L-Thyroxine sodium | 2-Thiouracil | Propylthiouracil | L-Thyroxine | Carbimazole | Resmetirom | Liothyronine | PCO371 | 2,2-BIS(2-HYDROXY-5-BIPHENYLYL)PROPANE | DS08210767 | Liothyronine sodium | Tiratricol |
相關庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | ReFRAME 相關化合物庫 | 內分泌激素分子庫 | NO PAINS 化合物庫 | 核受體化合物庫 | 臨床期小分子藥物庫 | 藥物功能重定位化合物庫 | 兒童藥物庫 | 人代謝物化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
詢價 |
VIP1年
|
青島愷潤生物醫(yī)藥科技有限公司
|
2024-11-02 | |
詢價 |
VIP2年
|
寶雞締都醫(yī)藥化工有限公司
|
2024-12-09 | |
詢價 |
VIP3年
|
湖北魏氏化學試劑股份有限公司
|
2024-12-20 | |
詢價 |
上海瀚香生物科技有限公司
|
2024-07-18 |